Description of medical serviceMeasurement of Programmed Death Ligand 1 (PD-L1) levels in tumour material from a patient diagnosed with NSCLC to determine if requirements are fulfilled for access to cemiplimab (a PD-1 inhibitor), under the Pharmaceutical Benefits Scheme.
Description of medical conditionThe applicant’s response is: ‘Lung cancer is the leading cause of cancer death in Australia and worldwide. At least 50% of lung cancer cases are stage III or IV at diagnosis. The 5-year relative survival for stage III lung cancer is 17.1% and for stage IV only 3.2%. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases. The majority of NSCLC lack defined mutations (such as epidermal growth factor receptor and anaplastic lymphoma kinase) that can be targeted by tyrosine kinase inhibitors. NSCLC is most commonly treated with platinum-based chemoradiation and more recently immunotherapies, inhibiting programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1).'
Reason for applicationAmendment to existing MBS item 72814
Medical Service TypeInvestigative
Previous Application Number/sNot Applicable
Application FormApplication Form (PDF 1336 KB)
Application Form (Word 185 KB)
Consultation SurveyConsultation Survey (PDF 559 KB)
Consultation Survey (Word 70 KB)
Public Summary DocumentPublic Summary Document (PDF 390 KB)
Public Summary Document (Word 74 KB)